Emerging therapies for heart failure: renal mechanisms and effects.
Improved understanding of the pathophysiology of salt and water homeostasis has provided a foundation for explaining the renal mechanisms of emerging therapies for heart failure, as well as why renal function might potentially be improved or harmed. These aspects are reviewed in this article for a number of newer therapies including adenosine, endothelin, and vasopressin receptor antagonists, as well as extracorporeal ultrafiltration. An appreciation of the complexity and sometimes opposing pathways of these approaches may explain their limited efficacy in early trials, in which there has not been a substantial improvement in patient or renal outcomes. In that there is often a balance between beneficial and maladaptive receptor actions and neurohumoral responses, this physiologic approach also provides insight into the rationale for combining therapies. Multi-agent strategies may thus maximize their effectiveness while minimizing adverse effects and tolerance. In this paper, the theoretical impact of the emerging agents based on their mechanism of action and pathophysiology of the disease is initially addressed. Then, the available clinical evidence for each class of drugs is reviewed with special emphasis on their effect on kidney-related parameters. Finally, a general overview of the complexity of the interpretation of trials is offered along with a number of potential explanations for the observed results.
Kazory
Amir
A
Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, 1600 SW Archer Road, Box 100224, Gainesville, FL 32610-0224, USA. amir.kazory@medicine.ufl.edu
Ross
Edward A
EA
D058916:Adenosine A1 Receptor Antagonists / Q000627:therapeutic use; D065092:Antidiuretic Hormone Receptor Antagonists; D059347:Cardio-Renal Syndrome / Q000150:complications / Q000503:physiopathology*; D002986:Clinical Trials as Topic; D065128:Endothelin Receptor Antagonists; D006333:Heart Failure / Q000150:complications / Q000628:therapy*; D006801:Humans
D058916:Adenosine A1 Receptor Antagonists; D065092:Antidiuretic Hormone Receptor Antagonists; D065128:Endothelin Receptor Antagonists
J Card Fail. 2008 Feb;14(1):1-5
18226766
Am J Cardiol. 2003 Jan 15;91(2):245-8
12521645
J Am Coll Cardiol. 2005 Dec 6;46(11):2043-6
16325039
Eur J Heart Fail. 2001 Aug;3(4):457-61
11511432
J Am Coll Cardiol. 2009 Feb 17;53(7):589-596
19215833
J Am Coll Cardiol. 2003 Jan 15;41(2):204-10
12535809
J Am Coll Cardiol. 2000 Jan;35(1):56-9
10636259
Lancet. 1988 May 7;1(8593):1033-5
2896877
J Card Fail. 2007 Oct;13(8):609-17
17923351
J Card Fail. 2006 Jun;12(5):349-52
16762797
Congest Heart Fail. 2009 Jul-Aug;15(4):210-1
19627301
Eur Heart J. 1997 Feb;18(2):254-8
9043842
N Engl J Med. 2005 Jul 14;353(2):113-6
16014879
N Engl J Med. 2001 Aug 23;345(8):574-81
11529211
J Am Coll Cardiol. 2007 Feb 13;49(6):675-83
17291932
J Am Coll Cardiol. 2003 May 7;41(9):1452-7
12742280
J Am Coll Cardiol. 2005 Dec 6;46(11):2047-51
16325040
Am Heart J. 2001 Aug;142(2):340-9
11479476
Biochem Biophys Res Commun. 1988 Sep 30;155(3):1244-7
3052444
J Card Fail. 2006 Dec;12(9):707-14
17174232
Circulation. 2008 Jan 29;117(4):e25-146
18086926
Eur J Heart Fail. 2008 Feb;10(2):176-87
18242127
J Clin Invest. 1989 Sep;84(3):1032-5
2547837
Lancet. 2004 Jul 24-30;364(9431):347-54
15276394
Heart. 2006 Jun;92(6):798-803
16339819
J Am Soc Nephrol. 1991 Aug;2(2):150-5
1954327
Circulation. 2002 Mar 19;105(11):1348-53
11901047
J Am Coll Cardiol. 2007 Oct 16;50(16):1551-60
17936154
J Am Coll Cardiol. 2008 Nov 4;52(19):1540-5
19007589
Am Heart J. 2010 Apr;159(4):505-7
20362706
Circ Heart Fail. 2009 Nov;2(6):523-31
19919976
Circulation. 1997 Mar 18;95(6):1363-5
9118500
J Am Coll Cardiol. 2007 Aug 14;50(7):600-6
17692744
J Card Fail. 2008 Oct;14(8):631-40
18926433
J Am Coll Cardiol. 2006 Apr 18;47(8):1615-21
16630999
Circulation. 2001 Feb 20;103(7):973-80
11181472
Eur J Heart Fail. 2004 Aug;6(5):601-9
15302008
Circulation. 1990 Nov;82(5):1724-9
2146040
Circ Res. 2003 Oct 17;93(8):759-66
12970111
J Card Fail. 2005 Feb;11(1):12-20
15704058
Heart Fail Rev. 2009 Dec;14(4):243-53
19876734
Chest. 2001 Aug;120(2):460-6
11502644
J Am Coll Cardiol. 2007 Jun 5;49(22):2151-9
17543634
Circulation. 2003 Jun 3;107(21):2690-6
12742979
Hypertension. 2008 Sep;52(3):452-9
18678788
Circulation. 2001 Nov 13;104(20):2417-23
11705818
J Card Fail. 2003 Jun;9(3):227-31
12815573
Circulation. 2002 Nov 19;106(21):2666-72
12438291
J Card Fail. 2008 Aug;14(6):515-20
18672200
JAMA. 2004 Apr 28;291(16):1963-71
15113814
Int J Cardiol. 2010 Aug 6;143(1):1-3
20207034
Am J Cardiol. 2008 Jun 2;101(11A):89E-103E
18514634
J Card Fail. 2008 Oct;14(8):641-7
18926434
Congest Heart Fail. 2008 Nov-Dec;14(6):298-301
19076851
Circulation. 2006 Nov 21;114(21):2240-50
17088462
Eur J Heart Fail. 2008 Feb;10(2):165-9
18279771
N Engl J Med. 1999 Aug 19;341(8):577-85
10451464
JAMA. 2007 Mar 28;297(12):1319-31
17384437
Heart. 2009 Jul;95(13):1047-51
19261603
Br J Pharmacol. 2007 Aug;151(7):1025-32
17558436
Biochem Biophys Res Commun. 1988 Aug 30;155(1):167-72
2458103
Am J Physiol Renal Physiol. 2006 Feb;290(2):F273-8
16189291
Circulation. 2006 Oct 10;114(15):1572-80
17015793
CMAJ. 2007 Mar 13;176(6):S1-44
17353516
Am J Physiol Lung Cell Mol Physiol. 2005 Nov;289(5):L685-95
16214819
JAMA. 2007 Nov 7;298(17):2009-19
17986694
Mol Cell Biochem. 2004 Apr;259(1-2):163-8
15124920
J Hypertens. 1998 Aug;16(8):1081-98
9794709